Business
Reem Capital Corp. Announces Proposed Business Combination with Israeli Based Kalron Holdings Ltd.
Calgary, Alberta--(Newsfile Corp. - April 4, 2022) - Reem Capital Corp.   (TSXV: REEM) ("...
About this update from Seegnal Inc.
[{"type":"text","content":"Reem Capital Corp. Announces Proposed Business Combination with Israeli Based Kalron Holdings Ltd.Calgary, Alberta--(Newsfile Corp. - April 4, 2022) - Reem Capital Corp. (TSXV: REEM) (\"REEM\") is pleased to announce details concerning a proposed arm's length business combination (the \"Transaction\") with Kalron Holdings Ltd. (\"Kalron\"), a corporation formed under the laws of Israel.Overview of ReemReem is a \"capital pool company\" under the policies of the TSX Venture Exchange (the \"Exchange\") and it is intended that the Transaction will constitute the \"Qualifying Transaction\" of Reem, as such term is defined in Exchange Policy 2.4 - Capital Pool Companies. The common shares of Reem (the \"Reem Common Shares\") are currently listed on the Exchange and Reem is a reporting issuer in the provinces of British Columbia, Alberta, and Ontario. Reem was incorporated under the Business Corporations Act (British Columbia) (the \"BCBCA\") on March 29, 2021. Overview of Kalron Holdings Ltd (\"Kalron\") and Seegnal eHealth Ltd (\"Seegnal\")Kalron is a privately-held holding corporation that was established under the laws of Israel in 2017. Kalron is the sole shareholder of Seegnal, an Israeli based corporation which had operated under Teva Pharmaceuticals Industries Ltd. (\"Teva\") until its purchase by Kalron in December 2017. Seegnal provides patient-tailored software as a service (SAAS) system for one-glance managing & mitigating drug related problems while providing decision support to healthcare professionals at the point of care. Seegnal has developed, owns and is marketing a concept of addressing the need of detecting and solving drug-related problems, which has been determined as the fourth leading cause of mortality in developed countries.1 Seegnal's SAAS based software platform is a patient-tailored, clinicians'-friendly drug-related problem solution. Seegnal exclusively integrates at the point-of-care, unique patients'-specific data like genetics, food, results of lab tests, ECG, smoking and the effects of many concomitant medications, while delivering accuracy, sensitivity and specificity. Seegnal is currently selling its SAAS-based platform in the State of Israel and in the UAE. To date, Seegnal has also signed distribution agreements with several major entities in the US which are well established ke...